Samsung Biologics secures half of Japans top 10 pharmas as clients

Samsung Biologics secures half of Japans top 10 pharmas as clients

Samsung Biologics Co is accelerating its expansion in Japan, the world's third-largest pharmaceutical market. The South Korean company has signed contracts with half of Japan's top 10 pharmaceutical and biotech companies, rapidly strengthening its presence in the region, according to a report by Pulse, the English service of Maeil Business Newspaper Korea.